References:
1. Baron F, Canti L, Ariën KK, et al. Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients. Front Immunol . 2022;13:827242.
2. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med . 2021;385(21):1941–1950.
3. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19. New England Journal of Medicine . 2022;386(23):2188–2200.
4. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature . 2022;602(7898):671–675.
5. Sullivan DJ, Gebo KA, Shoham S, et al. Early Outpatient Treatment for Covid-19 with Convalescent Plasma. N Engl J Med . 2022;386(18):1700–1711.
6. Thompson MA, Henderson JP, Shah PK, et al. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol . 2021;
7. Hueso T, Godron A-S, Lanoy E, et al. Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis.Leukemia . 2022;36(4):1025–1034.
8. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med . 2021;27(11):2032–2040.
9. Gallian P, Le Cam S, Brisbarre N, et al. COVID-19 convalescent plasma: Evolving strategies for serological screening in France.Vox Sang . 2022;117(4):606–610.
10. Blennow O, Salmanton-García J, Nowak P, et al. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report. Am J Hematol . 2022;97(8):E312–E317.
11. Hueso T, Pouderoux C, Péré H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood . 2020;136(20):2290–2295.
12. Lang-Meli J, Fuchs J, Mathé P, et al. Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency. J Clin Immunol . 2022;42(2):253–265.
13. Rahman F, Liu STH, Taimur S, et al. Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: Experience at large transplant center in New York City. Clin Transplant . 2020;34(12):e14089.
14. Gupta A, Kute VB, Patel HV, et al. Feasibility of Convalescent Plasma Therapy in Kidney Transplant Recipients With Severe COVID-19: A Single-Center Prospective Cohort Study. Exp Clin Transplant . 2021;19(4):304–309.
Legend table 1: Baseline characteristics of the 75 immunocompromised patients infected with the BA.1 or BA.2 Omicron subvariants of SARS-CoV-2 and treated with CCP. CCP: COVD-19 convalescent plasma. BAU: Binding antibody unit, WHO score 5: Hospitalized, oxygen by mask or nasal prongs, WHO 6: Hospitalized, oxygen by non-invasive ventilation or high flow.
Legend figure 1: Overall survival of whole cohort (A ) Overall survival according to underlying immunosuppression (B ) and COVID-19 severity at the time of CCP infusion (C ). AID: autoimmune disease; HM: hematological malignancy; SOTR: solid organ transplant recipient, WHO score 5: Hospitalized, oxygen by mask or nasal prongs, WHO 6: Hospitalized, oxygen by non-invasive ventilation or high flow.